The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Lymphatic DiseaseHIV Infections
Interventions
DRUG

Zidovudine

Trial Locations (22)

11030

Northshore Hosp / Cornell Univ, Manhasset

19107

Buckley Braffman Stern Med Associates, Philadelphia

19146

Graduate Hosp, Philadelphia

20007

Georgetown Univ Med Ctr, Washington D.C.

23298

Med College of Virginia, Richmond

27103

Bowman Gray School of Medicine / North Carolina Baptist Hosp, Winston-Salem

28207

Nalle Clinic, Charlotte

29425

Med Univ of South Carolina, Charleston

30303

Emory Univ School of Medicine, Atlanta

33612

Univ of South Florida, Tampa

38103

Regional Med Ctr at Memphis, Memphis

53226

Milwaukee County Med Complex, Milwaukee

77030

Baylor College of Medicine, Houston

77550

Univ TX Galveston Med Branch, Galveston

84132

Dr Kristen Reis, Salt Lake City

Univ of Utah School of Medicine, Salt Lake City

87131

Univ of New Mexico Hlth Sciences Ctr / Dept of Med, Albuquerque

92037

LaJolla Veterans Administration Med Ctr, La Jolla

92103

AIDS Clinical Trials Group, San Diego

97201

Oregon Health Sciences Univ, Portland

331361013

Univ of Miami School of Medicine, Miami

972103079

Good Samaritan Hosp, Portland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002048 - The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III) | Biotech Hunter | Biotech Hunter